Diabetes drug repurposed in fight against leading cause of blindness
NCT ID NCT07174687
Summary
This study is testing whether dapagliflozin, a medication typically used for diabetes, can slow the progression of geographic atrophy, an advanced stage of age-related macular degeneration that causes vision loss. About 70 participants with this specific eye condition will take either the drug or a placebo pill daily for one year. Researchers will use eye scans to measure if the medication reduces the growth of damaged areas on the retina.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.